Patents by Inventor Jennifer Kozak

Jennifer Kozak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR
    Publication number: 20240158389
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Application
    Filed: October 3, 2023
    Publication date: May 16, 2024
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E.L. Brandt, Robert Murray McKinnell
  • NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20240132520
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat inflammatory bowel diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: September 5, 2023
    Publication date: April 25, 2024
    Inventors: Ryan Hudson, Jennifer Kozak, Paul R. Fatheree, Dante D. Podesto, Gary E.L. Brandt, Melissa Fleury, Anne-Marie Beausoleil, Xiaojun Huang, Venkat R. Thalladi
  • SUBSTITUTED PYRIMIDINES AND METHODS OF USE
    Publication number: 20230399312
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Application
    Filed: April 27, 2023
    Publication date: December 14, 2023
    Inventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
  • Pyrimidine compound as JAK kinase inhibitor
    Patent number: 11814377
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: November 14, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson, Marta Dabros, Jerry Nzerem
  • Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
    Patent number: 11780852
    Abstract: Disclosed are methods for treating Crohn's disease using a compound of the formula: or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: October 10, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Dante D. Podesto, Xiaojun Huang, Venkat R. Thalladi
  • ALK5 inhibitors
    Patent number: 11730720
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: August 22, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Svitlana Kulyk, Christina Owens, Steven D. E. Sullivan, Jennifer Kozak, Adam D. Hughes
  • SUBSTITUTED PYRIDINES AND METHODS OF USE
    Publication number: 20230218597
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Application
    Filed: January 4, 2023
    Publication date: July 13, 2023
    Inventors: Christina Owens, Svitlana Kulyk, Steven D.E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Chen Zhao, Erik Fenster, Adam D. Hughes
  • Substituted pyrimidines and methods of use
    Patent number: 11673879
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: June 13, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
  • Substituted pyridines and methods of use
    Patent number: 11590116
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: February 28, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Christina Owens, Svitlana Kulyk, Steven D. E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Erik Fenster, Adam D. Hughes
  • PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR
    Publication number: 20220396573
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Application
    Filed: June 30, 2022
    Publication date: December 15, 2022
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E.L. Brandt, Robert Murray McKinnell
  • SUBSTITUTED PYRIMIDINES AND METHODS OF USE
    Publication number: 20220372015
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Application
    Filed: March 30, 2021
    Publication date: November 24, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
  • Pyrimidine compound as JAK kinase inhibitor
    Patent number: 11420965
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: August 23, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E. L. Brandt, Robert Murray McKinnell
  • Pyrimidine compounds as JAK kinase inhibitors
    Patent number: 11110095
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: September 7, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Melissa Fleury, Paul R. Fatheree, Anne-Marie Beausoleil, Dante D. Podesto, Xiaojun Huang
  • PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR
    Publication number: 20210214349
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Application
    Filed: March 30, 2021
    Publication date: July 15, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E.L. Brandt, Robert Murray McKinnell
  • NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20210179637
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat inflammatory bowel diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 17, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Dante D. Podesto, Xiaojun Huang, Venkat R. Thalladi
  • ALK5 INHIBITORS
    Publication number: 20210154178
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Application
    Filed: December 4, 2020
    Publication date: May 27, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Svitlana Kulyk, Christina Owens, Steven D.E. Sullivan, Jennifer Kozak, Adam D. Hughes
  • SUBSTITUTED PYRIDINES AND METHODS OF USE
    Publication number: 20210154179
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Application
    Filed: November 20, 2020
    Publication date: May 27, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Christina Owens, Svitlana Kulyk, Steven D.E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Erik Fenster, Adam D. Hughes
  • Pyrimidine compound as JAK kinase inhibitor
    Patent number: 10988470
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: April 27, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson, Robert Murray McKinnell, Gary E. L. Brandt
  • ALK5 inhibitors
    Patent number: 10952996
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: March 23, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Svitlana Kulyk, Christina Owens, Steven D. E. Sullivan, Jennifer Kozak, Adam D. Hughes
  • Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
    Patent number: 10947254
    Abstract: Disclosed are methods for treating ulcerative colitis using a compound of the formula: or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: March 16, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Dante D. Podesto, Xiaojun Huang, Venkat R. Thalladi